White House signs $750 million deal with Abbott Labs to buy 150 million rapid coronavirus tests
- The United States signed a $750 million deal with
AbbottLaboratories for 150 million rapid coronavirustests.
- Abbot's BinaxNow test was granted emergency authorization by the Federal Drug Administration on Wednesday.
- The company also said it was preparing to "ship tens of millions of tests in September, ramping production to 50 million tests a month in October."
The United States signed a $750 million deal with Abbott Laboratories for 150 million rapid coronavirus tests, the White House announced Thursday.
"By strategically distributing 150 million of these tests to where they're needed most, we can track the virus like never before and protect millions of Americans at risk in especially vulnerable situations," Department of Health and Human Services Secretary Alex Azar said in a statement.On Wednesday, the Federal Drug Administration granted the company emergency authorization for its new COVID-19 test.
In a statement, the company also said it was preparing to "ship tens of millions of tests in September, ramping production to 50 million tests a month in October."According to the Wall Street Journal, that total in October would be double the number of tests conducted in July.
The Journal reported that the test is about the size of a credit card and can be given in a doctor's or school nurse's office.The contract could help expand
More than 5.8 million Americans have been diagnosed with COVID-19 in the US so far, and over 180,000 have died.
Experts have called for more testing to help get the outbreak under control.Abbott said in their statement that their BinaxNow antigen test had 97% sensitivity rate, which is the percent of positive cases a test accurately detects.
The Journal reported that lab-based PCR tests are generally thought to be more reliable and less sensitive to rapid antigen tests.
"This new COVID-19 antigen test is an important addition to available tests because the results can be read in minutes, right off the testing card. This means people will know if they have the virus in almost real-time," Jeff Shuren, director of the FDA's Center for Devices and Radiological Health said in a statement. "Due to its simpler design and the large number of tests the company anticipates making in the coming months, this new antigen test is an important advancement in our fight against the pandemic."
- Stocks to track on March 4 — HDFC, Airtel, Infosys, Adani Ports and others
- Deficit budget tabled in Arunachal Assembly with focus on
- DPR for piped water connection project announced in Rajasthan Budget to be ready by Aug 30: BD Kalla
- Budget session of Karnataka legislature to begin on Thursday
- Bharat Biotech’s Covaxin shows 81% efficacy after second dose in phase 3 trials